No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
FRANCE — The European Union’s medicines regulator has given a new stage of approval for Dupixent, Sanofi, and Regeneron’s product to treat children as young as 6 months old with…
Read More
FRANCE — French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview. The…
Read More
SINGAPORE — GSK, Sanofi, and Takeda are set to collaborate with researchers from the Agency for Science, Technology and Research (A*STAR), National University of Singapore (NUS), Nanyang Technological University, Singapore…
Read More
HONG KONG —Insilico Medicine, a clinical-stage AI-driven drug discovery company, has signed a US$1.2 billion multi-year, multi-target strategic research collaboration with Sanofi. Sanofi is a global pharmaceutical company headquartered in…
Read More
BELGIUM — The European Commission (EC) has granted approval for AstraZeneca and Sanofi’s Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTI) in newborns and infants.…
Read More
GERMANY — BioMed X, a German independent research institute has formed a research collaboration with Sanofi to use artificial intelligence (AI) in drug development. The preliminary model will focus on…
Read More
FRANCE – Sanofi has collaborated with the Californian biotechnology company Scribe Therapeutics to develop new cancer cell therapies. Under the terms of the deal, Sanofi picks up non-exclusive rights to…
Read More
INDIA – Pharma majors GSK and Sanofi may have a negative impact on their revenues after the central government has included drugs manufactured by these companies into the updated national…
Read More
FRANCE- Sanofi has decided to stop developing amcenestrant, a once-promising breast cancer medication, after a second unsuccessful clinical trial, striking a setback to its pipeline of potential new medicines. The…
Read More
FRANCE – French Pharma giant Sanofi has halted development of lademirsen, discovered by Regulus Therapeutics, after the program failed a Phase II interim analysis. Sanofi added that the move was…
Read More